Our mission is to provide innovative vision products that enhance quality of life by helping people see better. From vision research to eye health, learn more at Alcon.com.

Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With an over 75-year heritage, we are the largest eye care device company in the world, with complementary businesses in Surgical and Vision Care.

Alcon provides Eye Care Professionals comprehensive eye health education, hands-on experiential learning opportunities and cutting-edge virtual reality technology for immersive training experiences at our state-of-the-art facilities around the world.

Alcon offers professional development opportunities and experience as a global leader in eye care. Search Alcon pharmaceutical jobs, internships and more at Alcon.com.

Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation

Nov 12, 2024 · Alcon reported diluted earnings per share of $0.53 and core diluted earnings per share 2 of $0.81 in the third quarter of 2024. "Our third quarter results reflect our broad geographic footprint and excellent execution by our team.

Apr 2, 2024 · “All research and advancements we are bringing to ASCRS share one underlining theme: Alcon's eye care innovations empower surgeons to achieve optimal outcomes for their patients,” said Sergio Duplan, President of North America at Alcon.

3 days ago · Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives.

At the beginning of 2022, Alcon reaffirmed our commitment in glaucoma with our acquisition of Ivantis, Inc. Our goal was simple: to introduce Hydrus ® Microstent, a minimally invasive glaucoma surgery (MIGS) device, proven to lower intraocular pressure in patients with mild to moderate primary open angle glaucoma in conjunction with cataract ...

Feb 19, 2025 · New first-line laser treatment for the nearly 5 million Americans diagnosed with glaucoma1,2 Automated device enables a streamlined workflow without a gonio lens or manual aiming2 Voyager Direct Selective Laser Trabeculoplasty (DSLT) will be launched at the American Glaucoma Society annual meeting in Washington, D.C. Alcon (SIX/NYSE: ALC), the ...